Showing results (61-70 of 193) with videos related to
Sort By:
Pageof 20
Nuclear Medicine and Biology|August 25, 2015
In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin (111)In-radioligandsAikaterini Kaloudi, Berthold A Nock, Emmanouil Lymperis, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 5, 2006
Anticancer activity of targeted proapoptotic peptidesAstrid Capello, Eric P Krenning, Bert F Bernard, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 10, 2021
Dosimetric Evaluation of the Effect of Receptor Heterogeneity on the Therapeutic Efficacy of Peptide Receptor Radionuclide Therapy: Correlation with DNA Damage Induction and In Vivo SurvivalGiulia Tamborino, Julie Nonnekens, Marijke De Saint-Hubert, et al.Best Practice & Research. Clinical Gastroenterology|September 27, 2005
Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapyJaap J M Teunissen, Dik J Kwekkeboom, Marion de Jong, et al.Pharmaceuticals (Basel, Switzerland)|September 23, 2022
Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine TumorsSofia Koustoulidou, Maryana Handula, Corrina de Ridder, et al.Cancers|October 13, 2021
Comparing the Effect of Multiple Histone Deacetylase Inhibitors on SSTR2 Expression and [<sup>111</sup>In]In-DOTATATE Uptake in NET CellsMaria J Klomp, Simone U Dalm, Peter M van Koetsveld, et al.Contrast Media & Molecular Imaging|May 22, 2015
Optimized time-resolved imaging of contrast kinetics (TRICKS) in dynamic contrast-enhanced MRI after peptide receptor radionuclide therapy in small animal tumor modelsJoost Haeck, Karin Bol, Sander Bison, et al.Cancers|April 3, 2021
Cancer-Associated Fibroblasts as Players in Cancer Development and Progression and Their Role in Targeted Radionuclide Imaging and TherapySofia Koustoulidou, Mark W H Hoorens, Simone U Dalm, et al.European Journal of Nuclear Medicine and Molecular Imaging|January 19, 2005
Radiolabelling DOTA-peptides with 68GaWouter A P Breeman, Marion de Jong, Erik de Blois, et al.Cancer Biotherapy & Radiopharmaceuticals|November 25, 2003
Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitroAstrid Capello, Eric P Krenning, Wout A P Breeman, et al.Pageof 20